Article
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Journal of viral hepatitis - 1 Oct 2018
Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore G J, Petoumenos K, Applegate T L, Tu E, Marks P, Pagani N, Grebely J, Nelson M, Matthews G V
Abstract excerpt
Paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 12 weeks are approved for treatment of chronic HCV genotype 1 infection. This study assessed the efficacy of shortened duration paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin for 8 weeks among people with recent HCV infection. In this open-label single-arm trial conducted in Australia, England and New Zealand,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.